Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump
Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump
Read also
Senhwa Biosciences CX-5461
Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value
FDA Grants Breakthrough Therapy Designation to Olomorasib
FDA Grants Breakthrough Therapy Designation to Olomorasib With Pembrolizumab for NSCLC
Clene Inc
Clene Inc. announces preclinical data showing CNM-Au8 enhances cellular health in Parkinson’s disease models, supporting further clinical development
Gelteq
Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market
